CLK4 and cancer: Silencing CLK4 in an aggressive mesenchymal‐like subtype (MES) of TNBC reduces the expression of genes involved in metastasis and lessens the invasive behavior of these cancer cells.[15] Therefore, CLK4 represents a promising therapeutic target for development.